Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway

Table 1. Correlation between eIF6 and clinicopathologic characteristics in 184 OSCC cases

Pathologic characteristics	n	Overexpression (number of cases)	Nonoverexpression (number of cases)	P value
Age, years
≥ 60	98	53	45	0.1951
<60	86	46	40
Sex
Male	114	57	57	0.7918
Female	70	42	28
Smoking
Yes	76	42	34	0.2070
No	108	60	48
Drinking
Yes	90	49	41	0.2126
No	94	53	41
Location
Palate	10	4	6	0.7236
Tongue	63	33	30
Gingiva	35	21	14
Buccal	59	33	26
Mouth floor	17	8	9
Tumor stage
T1	83	35	48	T1 vs T2 = 0.0123
T2	74	46	28	T1 vs T3–4 = 0.0013
T3–T4	27	21	6
Lymph node status
N0	99	39	60	N0 vs N1 = 0.0187
N1	39	24	15	N0 vs N2–3 <0.0001
N2–3	46	35	11
Clinical grade
I	49	20	29	I vs II–III = 0.0005
II–III	67	49	18	I vs IV <0.0001
IV	68	58	10
Pathological grade
I	107	58	49	I vs II = 0.9052
II	58	32	26	I vs III = 0.7406
III	18	9	9

The P values represent probabilities for eIF6 expression levels between variable subgroups determined by a ^χ2 test.

ISSN: 1478-811X